TYK2 has been identified as a HSP90 client protein [58], and in T-ALL, pharmacological inhibition of HSP90 led to TYK2 degradation, reduced STAT1 phosphorylation, and subsequent BCL2 down-expression [78]. Here, TYK2 is linked to acute lymphoblastic leukemia.